Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial
Authors' conclusion
Fracture reductions with single-dose or 5-yearly zol appear greater during years 5 to 10 than years 0 to 5. The risk reductions are broadly consistent across this cohort and independent of baseline or change in BMD. This suggests that routine BMD monitoring may not be necessary for low-risk women considering the option of less frequent zol for long-term fracture risk reduction.
Study context
- Population
- Postmenopausal women aged 50 to 60 years with bone mineral density (BMD) T-score at lumbar spine, femoral neck or total hip between 0 and −2.5; 2012 to 2023
- Participants
- 1,054 women
- Comparison
- 5-yearly zol or single-dose zol vs placebo
- Primary endpoint
- Morphometric vertebral fractures, major osteoporotic and any fractures; effects over time and across baseline variables
- Follow-up
- 10 years
Methodological details10-year, prospective, double-blind, placebo-controlled, single clinical research center
- 10-year
- Prospective
- Double-blind
- Placebo-controlled
- Single clinical research center
Primary result
As reported in the abstract
Morphometric vertebral fractures · years 5 to 10
Risk reduction
58%
95% CI 21%–77%
zol-zol
Risk reduction
57%
95% CI 21%–77%
zol-placebo
Original publication
Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial. J Clin Endocrinol Metab. Published 18 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →